Meeder Asset Management Inc. Purchases 23,943 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Meeder Asset Management Inc. increased its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 32,355.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,017 shares of the biopharmaceutical company's stock after purchasing an additional 23,943 shares during the period. Meeder Asset Management Inc.'s holdings in TG Therapeutics were worth $947,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of TGTX. Clearbridge Investments LLC bought a new position in shares of TG Therapeutics in the fourth quarter valued at approximately $55,237,000. Raymond James Financial Inc. bought a new position in shares of TG Therapeutics during the 4th quarter worth $14,508,000. Norges Bank purchased a new stake in TG Therapeutics during the fourth quarter valued at about $12,085,000. Penn Capital Management Company LLC bought a new stake in shares of TG Therapeutics in the fourth quarter valued at approximately $10,577,000. Finally, First Trust Advisors LP raised its holdings in TG Therapeutics by 871.7% during the 4th quarter. First Trust Advisors LP now owns 275,496 shares of the biopharmaceutical company's stock valued at $8,292,000 after acquiring an additional 247,145 shares during the period. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Trading Down 1.4%

Shares of TGTX traded down $0.48 during mid-day trading on Friday, reaching $35.02. The company's stock had a trading volume of 2,316,464 shares, compared to its average volume of 1,512,933. The stock has a market cap of $5.56 billion, a PE ratio of 145.92 and a beta of 1.95. The company's fifty day moving average price is $36.83 and its two-hundred day moving average price is $36.01. TG Therapeutics, Inc. has a 52 week low of $16.65 and a 52 week high of $46.48. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The company had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. During the same period last year, the company posted ($0.07) EPS. The business's revenue for the quarter was up 90.4% compared to the same quarter last year. On average, analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 price target on the stock in a research report on Thursday, July 10th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $43.80.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the sale, the director directly owned 228,816 shares of the company's stock, valued at approximately $8,452,463.04. The trade was a 4.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 10.64% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.